TRAMANT: phase II study of maintenance therapy with trabectedin vs trabectedin + PLD after trabectedin + PLD in relapsed ovarian cancer recurring 6-12 months after platinum based chemotherapy



Main inclusion/exclusion criteria:

-patients must be in SD/PR/CR after 6-8 cycles of PLD+trabectedin

-patients must have received no more than 3 previous lines of chemotherapy

-patients must have measurable or evaluable disease

-patients must be able to receive dexamethasone or its equivalent

-patients with prior resistence to anthracyclines or PLD will be excluded

-patients with prior exposure to trabectedin will be excluded

CONTATTI

giorgio.valabrega@ircc.it

margherita.turinetto@ircc.it

0119933842

MITO 30: phase II study of trabectedin and olaparib for platinum-resistant ovarian cancer

High grade serous or endometrioid platinum resistant/refractory ovarian cancer

→

Trabectedin 1.1 mg/mq i.v. (24h infusion) q3w + olaparib 150 mg BID until toxicity or progression

Main inclusion/exclusion criteria:

-at least one previous platinum-based regimen and no more than two previous lines of chemotherapy
-availability of tumor samples for central revision and translational analysis
-measurable disease (RECIST 1.1)
-patients must be able to receive dexamethasone or its equivalent
-patients with symptomatic metastatic brain or meningeal tumors will be excluded

CONTATTI
giorgio.valabrega@ircc.it
giulia.scotto@ircc.it
margherita.turinetto@ircc.it
0119933842

OReO: phase IIIb of olaparib maintenance retreatment in patients with EOC previously treated with a PARPi



Main inclusion/exclusion criteria:

-documented *BRCA1/2* status (**only BRCA-negative cohort open)**

-patients must have received one prior PARPi therapy

-patients must be in response after a platinum-based chemotherapy regimen and have received at least 4 cycles of treatment

-patients must **not** have received bevacizumab during this course of treatment

-patients must have available tumor samples

-patients with sintomatic metastatic brain or meningeal tumors will be excluded

CONTATTI

giorgio.valabrega@ircc.it
giulia.scotto@ircc.it
valentina.tuninetti@ircc.it
0119933842